Framingham, MA -- June 19, 2008 -- GTC Biotherapeutics, Inc. (“GTC”) (Nasdaq: GTCB) will webcast its 2008 Annual Meeting of Stockholders on June 24, 2008 starting at approximately 10:00 a.m. Eastern Time. The annual meeting is to be held at the Forefront Center for Meetings & Conferences in Waltham, Massachusetts. GTC expects to conduct the formal business portion of the meeting followed by a presentation to its stockholders.

To access the 2008 Annual Meeting live via the Internet, please log onto HYPERLINK "http://www.gtc-bio.com" www.gtc-bio.com approximately 15 minutes before the start of the meeting to allow for any software downloads that may be necessary. Following the webcast of the meeting, an archive will be available at the same address.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the meeting at HYPERLINK "http://www.earnings.com" www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

About GTC Biotherapeutics
GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC’s recombinant human antithrombin, has been approved for use in Europe and has begun the review process in the United States under a rolling Biologics License Application. In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa and IX, which are used for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site,http://www.gtc-bio.com.